Investigating how T cell microRNA-155 enhances immune responses in colon cancer treatment.
T cell expressed miR-155 promotes antitumor immunity and immune checkpoint blockade responses in colon cancer through repression of Ship1
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF UTAH · NIH-11034112
This study is looking at how a tiny molecule called microRNA-155 can help make cancer treatments work better for people with advanced colon cancer by boosting the immune system's ability to fight tumors that don't have many immune cells.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-11034112 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how T cell microRNA-155 can improve the effectiveness of immune checkpoint blockade therapy in patients with colon cancer. By manipulating this specific microRNA, the study aims to convert tumors that lack immune cells into ones that are rich in immune cells, thereby enhancing the body's ability to fight cancer. The approach involves examining the tumor microenvironment and how T cell activity can be modulated to promote better responses to existing therapies. Patients with advanced-stage colon cancer may benefit from this innovative strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced-stage colon cancer, particularly those who have not responded to standard immune checkpoint therapies.
Not a fit: Patients with early-stage colon cancer or those whose cancer is not advanced may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with colon cancer who currently do not respond well to existing therapies.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses through similar approaches, indicating potential for success in this area.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TANG, WILLIAM WEIHAO — UNIVERSITY OF UTAH
- Study coordinator: TANG, WILLIAM WEIHAO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.